Global cancer focus Hematogenix is a global cancer-focused life science company offering biomarker development and testing services across multiple regions including the US, Europe, China, and Asia-Pacific, presenting a broad cross-border collaboration and outsourcing opportunity for pharma and biotech clients.

Comprehensive service menu Their test menu spans Flow Cytometry, Molecular Genetics, NGS, Histology/IHC, Cytogenetics/FISH, Pathology, Digital Pathology and Image Analysis, enabling end-to-end support for research, development and implementation of targeted therapies—a compelling value proposition for integrated lab services.

Regulatory excellence With CAP accreditation, CLIA certification, and GCP compliance, Hematogenix demonstrates strong quality and regulatory readiness, which can shorten vendor qualification time and reduce risk for CROs, biotechs, and pharma partners pursuing clinical trials.

Expansion footprint Recent facility expansion in Shanghai and global laboratory network imply capacity growth and regional proximity benefits, suggesting sales opportunities in Asian markets where local testing capacity and rapid turnaround are critical.

Financial potential Revenue in the mid-range of tens of millions and a lean to mid-sized employee base indicate scalable partnerships for mid-to-late stage clinical programs, enabling tiered service engagements and predictable outsourcing pipelines.